Reducing Elevated Parathyroid Hormone to Protect Bone Strength in End-Stage Kidney Disease

Funding

TI is supported by grants K24HL150235 and U2CDK129917 from the NIH . TLN received research funding from Amgen for investigator-initiated study (Amgen 2018736; registered at ClinicalTrials.gov with study number NCT03960437). The funders did not have a role in defining the content of the manuscript. Tamara Isakova, MD, MMSc, and Thomas L. Nickolas, MD, MS. TI is supported by grants K24HL150235 and U2CDK129917 from the NIH. TLN received research funding from Amgen for investigator-initiated study (Amgen 2018736; registered at ClinicalTrials.gov with study number NCT03960437). The funders did not have a role in defining the content of the manuscript. TI has served as a consultant for Blueprint Partnership, Manchester, Ltd, and Walking Fish Therapeutics, Inc. TLN has received research funding from Amgen and served on the Scientific Advisory Board for Pharmacosmos. Received December 6, 2023, in response to an invitation from the journal. Accepted December 12, 2023, after editorial review by an Associate Editor and a Deputy Editor.